Cue Biopharma's CUE-221 beats Xolair in a Phase 2 chronic hives trial, sending shares up 30% as it eyes a pivotal study.
Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The ...
Welcome back to another edition of Endpoints Weekly! We’ll get to the headlines in just a bit, but be sure to check out the ...
Legend Biotech has tapped Novartis executive Ingrid Zhang as its new CEO at a time when the company is seeking its next act.
Six UK parliamentary committees ask the National Audit Office to probe the cost of the £1B UK-US pharma deal and its NHS ...
Endpoints takes its China biotech debate to DC: four Post-Hoc Live conversations on patents, FDA data, biosecurity and ...
CMS signaled drugmakers joining its Generous Medicaid rebate demo would be exempt from the Globe and Guard Medicare pilots, ...
Gilead expands lenacapavir HIV PrEP access in Latin America; Cloudbreak IPO probed; Sironax gets $125M from Novartis; Circle ...
Tech giants & startups like Google, OpenAI, Amazon, Anthropic, Whoop, Oura now offer AI assistants using medical records.
CART01; Ori bags $120M deal; Reckitt invests $600M in US; Astellas expands Ireland; Hovione opens NJ facility.
China's new five-year plan targets 20% annual pharma revenue growth and a quarter of the world's first-in-class drugs by 2030 ...
FDA grants accelerated approval to Ultragenyx's Sanfilippo gene therapy UX111, weeks after the biotech's Angelman Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results